跳至主要内容
临床试验/CTRI/2022/09/045280
CTRI/2022/09/045280尚未招募4 期

Efficacy and safety of tamsulosin vs. tamsulosin plus mirabegron in the management of overactive bladder in men with lower urinary tract symptoms

Dr Harmandeep Singh Chahal0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • newly diagnosed uncomplicated BPE of any size with predominant OABSS and an IPSS >7 without any medical contraindications to planned drug therapy or any absolute indication for surgery

排除标准

  • history of anaphylaxis/ hypersensitivity, drug therapy with metabolic interference to administered medication, prostatic/urethral surgery and other concomitant prostate disease/ cancers, clinical neurological disorders and or neurogenic bladder

研究者

发起方
Dr Harmandeep Singh Chahal

相似试验

Comparison of tamsulosin vs. tamsulosin plus... | 临床试验